Qiagen inks companion Dx deal with Bayer

Qiagen ($QGEN) has signed on with Bayer to develop companion diagnostics for Bayer's solid tumor treatments, using the company's QIAsymphony Dx platform. The duo didn't disclose financial details, but Qiagen will work on molecular tests to guide the use of Bayer's existing cancer drugs, and the two will collaborate on new patient-profiling technologies. The partnership adds to Qiagen's companion Dx portfolio, and the company said it's in the midst of more than 15 projects with pharma and biotech companies. Release

Suggested Articles

Seven developers will provide digital health solutions aimed at the COVID-19 pandemic, including smartphone apps, wearables and big data programs.

Illumina will drop $8 billion to reacquire its former spinout, which after nearly five years is nearing completion of its cancer-seeking blood test.

The CE Mark for the system’s fourth iteration follows a July 2019 approval from the FDA.